###begin article-title 0
Deaminase-Independent Inhibition of Parvoviruses by the APOBEC3A Cytidine Deaminase
###end article-title 0
###begin p 1
Current address: University of California San Francisco, San Francisco, California, United States of America
###end p 1
###begin p 2
Conceived and designed the experiments: IN YH DJP NRL MDW. Performed the experiments: IN DCL BNG YH EL. Analyzed the data: IN DCL BNG YH DJP NRL MDW. Wrote the paper: IN MDW.
###end p 2
###begin p 3
###xml 263 285 <span type="species:ncbi:272636">adeno-associated virus</span>
###xml 287 290 <span type="species:ncbi:272636">AAV</span>
###xml 709 712 <span type="species:ncbi:272636">AAV</span>
###xml 812 815 <span type="species:ncbi:272636">AAV</span>
###xml 846 866 <span type="species:ncbi:10794">minute virus of mice</span>
###xml 868 871 <span type="species:ncbi:10794">MVM</span>
###xml 953 956 <span type="species:ncbi:272636">AAV</span>
The APOBEC3 proteins form a multigene family of cytidine deaminases with inhibitory activity against viruses and retrotransposons. In contrast to APOBEC3G (A3G), APOBEC3A (A3A) has no effect on lentiviruses but dramatically inhibits replication of the parvovirus adeno-associated virus (AAV). To study the contribution of deaminase activity to the antiviral activity of A3A, we performed a comprehensive mutational analysis of A3A. By mutation of non-conserved residues, we found that regions outside of the catalytic active site contribute to both deaminase and antiviral activities. Using A3A point mutants and A3A/A3G chimeras, we show that deaminase activity is not required for inhibition of recombinant AAV production. We also found that deaminase-deficient A3A mutants block replication of both wild-type AAV and the autonomous parvovirus minute virus of mice (MVM). In addition, we identify specific residues of A3A that confer activity against AAV when substituted into A3G. In summary, our results demonstrate that deaminase activity is not necessary for the antiviral activity of A3A against parvoviruses.
###end p 3
###begin title 4
Author Summary
###end title 4
###begin p 5
###xml 408 411 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 472 477 <span type="species:ncbi:9606">human</span>
###xml 489 511 <span type="species:ncbi:272636">adeno-associated virus</span>
###xml 513 516 <span type="species:ncbi:272636">AAV</span>
###xml 1073 1076 <span type="species:ncbi:272636">AAV</span>
###xml 1090 1110 <span type="species:ncbi:10794">minute virus of mice</span>
###xml 1112 1115 <span type="species:ncbi:10794">MVM</span>
The APOBEC3 proteins constitute a family of seven cytidine deaminases. Cytidine deaminases are editing enzymes able to remove the amine group from cytidine in single-strand DNA (ssDNA) and RNA, converting it to uracil. APOBEC3 proteins have potent antiviral activity against retroviruses, retrotransposons, and DNA viruses. APOBEC3 generated high interest because of the ability of APOBEC3G (A3G) to inhibit HIV. APOBEC3A (A3A) is a member of the family that inhibits the human parvovirus adeno-associated virus (AAV) and the retrotransposon LINE-1. Parvoviruses are simple ssDNA viruses that do not require a retrotranscription step for their replication. In contrast to A3G, which is predominantly cytoplasmic, A3A is located in both the nucleus and cytoplasm. In addition, A3A consists of a single cytidine deaminase catalytic domain, whereas A3G has two. The dependence of the antiviral function on deaminase activity is controversial. In this study, we identify numerous A3A residues required for deaminase and antiviral activities. We show that A3A not only inhibits AAV but also the minute virus of mice (MVM). Importantly, we demonstrate that A3A does not require its deaminase activity to block the replication of both parvoviruses. Thus, exploiting the simplicity of parvoviruses together with the single-domain cytidine deaminase A3A, we are able to demonstrate that cytidine deaminase activity is not required for APOBEC3 mediated viral inhibition.
###end p 5
###begin title 6
Introduction
###end title 6
###begin p 7
###xml 213 216 213 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Conticello1">[1]</xref>
###xml 217 220 217 220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Wedekind1">[4]</xref>
###xml 320 323 320 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Harris1">[5]</xref>
###xml 324 327 324 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Cullen1">[7]</xref>
###xml 461 464 461 464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Sheehy1">[8]</xref>
###xml 465 469 465 469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Zhang2">[11]</xref>
###xml 726 729 726 729 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Chiu1">[6]</xref>
###xml 730 733 730 733 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Cullen1">[7]</xref>
###xml 734 738 734 738 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Mangeat1">[10]</xref>
###xml 739 743 739 743 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Okeoma1">[13]</xref>
###xml 902 906 902 906 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Chen1">[14]</xref>
###xml 422 452 <span type="species:ncbi:11676">human immunodeficiency virus 1</span>
###xml 454 459 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 486 491 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 559 588 <span type="species:ncbi:11723">simian immunodeficiency virus</span>
###xml 590 593 <span type="species:ncbi:11723?0.9432672590567327">SIV</span>
###xml 596 601 <span type="species:ncbi:9606">human</span>
###xml 635 656 <span type="species:ncbi:11786">murine leukemia virus</span>
###xml 658 661 <span type="species:ncbi:11786">MLV</span>
###xml 664 689 <span type="species:ncbi:11757">mouse mammary tumor virus</span>
###xml 691 695 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 702 719 <span type="species:ncbi:10407">hepatitis B virus</span>
###xml 721 724 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
###xml 760 765 <span type="species:ncbi:9606">human</span>
###xml 873 895 <span type="species:ncbi:272636">adeno-associated virus</span>
###xml 897 900 <span type="species:ncbi:272636">AAV</span>
Eukaryotes have evolved numerous innate immune defenses against invading pathogens. The apolipoprotein B mRNA-editing catalytic polypeptide-like 3 (APOBEC3) proteins comprise a family of seven cytidine deaminases [1]-[4] that may each form distinct intrinsic barriers to endogenous retrotransposons and invading viruses [5]-[7]. The most characterized member of the family is APOBEC3G (A3G), which restricts Vif-deficient human immunodeficiency virus 1 (HIV-1) [8]-[11]. In addition to HIV-1, the APOBEC3 proteins inhibit a diverse array of viruses including simian immunodeficiency virus (SIV), human T cell leukemia virus 1 (HTLV1), murine leukemia virus (MLV), mouse mammary tumor virus (MMTV), and hepatitis B virus (HBV) [6],[7],[10]-[13]. Interestingly, human APOBEC3A (A3A) lacks activity against retroviruses but dramatically inhibits replication of the parvovirus adeno-associated virus (AAV) [14]. The molecular mechanisms that govern specificity of APOBEC3 antiviral activity are not yet fully understood.
###end p 7
###begin p 8
###xml 133 136 133 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Conticello1">[1]</xref>
###xml 137 140 137 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Wedekind1">[4]</xref>
###xml 265 270 265 270 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">23&#8211;28</sub>
###xml 276 279 276 279 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#8211;4</sub>
###xml 396 398 396 398 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 494 498 494 498 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Betts1">[15]</xref>
###xml 499 503 499 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Prochnow1">[18]</xref>
###xml 844 848 844 848 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Cen1">[19]</xref>
###xml 849 853 849 853 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Wang1">[23]</xref>
###xml 952 955 952 955 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Jarmuz1">[2]</xref>
###xml 804 807 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
The APOBEC3 proteins share structural and functional features with zinc-dependent deaminases and possess cytidine deaminase activity [1],[4]. The cytidine deaminase domains (CDDs) of APOBEC3 proteins contain an active site with the conserved consensus motif H-X-E-X23-28-P-C-X2-4-C (where X is any amino acid). It has been proposed that the histidine and the two cysteine residues coordinate a Zn2+ ion, while the glutamic acid residue serves an essential role in catalysis as a proton shuttle [15]-[18]. APOBEC3 proteins contain either a single CDD (A3A, A3C and A3H) or two tandem CDDs (A3B, A3D/E, A3F and A3G). In the case of A3G, both domains contain an intact active site consensus sequence motif but only CDD2 appears to be catalytically active, while CDD1 is responsible for interaction with the HIV nucleocapsid proteins and packaging [19]-[23]. Sequence alignment shows that A3A is highly homologous to the C-terminus of A3B and A3G proteins [2].
###end p 8
###begin p 9
###xml 110 113 110 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Harris1">[5]</xref>
###xml 114 117 114 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Chiu1">[6]</xref>
###xml 118 122 118 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-GoilaGaur1">[24]</xref>
###xml 265 269 265 269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Cen1">[19]</xref>
###xml 270 274 270 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Luo1">[22]</xref>
###xml 275 279 275 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Wang1">[23]</xref>
###xml 280 284 280 284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Alce1">[25]</xref>
###xml 285 289 285 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Zennou1">[32]</xref>
###xml 452 455 452 455 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Harris2">[9]</xref>
###xml 456 460 456 460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Zhang2">[11]</xref>
###xml 461 465 461 465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Yu1">[33]</xref>
###xml 466 470 466 470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Aguiar1">[35]</xref>
###xml 568 572 568 572 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Yang1">[36]</xref>
###xml 690 694 690 694 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Mbisa1">[37]</xref>
###xml 695 699 695 699 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Schumacher1">[38]</xref>
###xml 878 882 878 882 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Holmes1">[39]</xref>
The mechanism of the antiviral activity of APOBEC3 proteins against retroviruses has been studied extensively [5],[6],[24]. APOBEC3 proteins are incorporated into virus particles, and encapsidation is mediated via interactions with Gag, viral RNA and cellular RNAs [19],[22],[23],[25]-[32]. Encapsidated A3G is delivered into target cells where it deaminates dC to dU on newly synthesized minus strand cDNAs during the process of reverse transcription [9]-[11],[33]-[35]. Deaminated genomes can be degraded by the action of the cellular base excision repair machinery [36], although recent reports suggest that uracil-DNA glycosylase 2 (UNG2) is not required for the A3G antiviral function [37],[38]. In addition, hypermutated proviruses will contain sequence changes that inactivate the virus by generating alternate splicing, premature translation, and nonfunctional proteins [39].
###end p 9
###begin p 10
###xml 125 129 125 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Holmes1">[39]</xref>
###xml 282 286 282 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Shindo1">[40]</xref>
###xml 287 291 287 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Bishop1">[42]</xref>
###xml 462 466 462 466 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Aguiar1">[35]</xref>
###xml 467 471 467 471 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Bishop1">[42]</xref>
###xml 472 476 472 476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Holmes2">[44]</xref>
###xml 581 585 581 585 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Mbisa1">[37]</xref>
###xml 586 590 586 590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Luo2">[45]</xref>
###xml 807 811 807 811 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Schumacher1">[38]</xref>
###xml 812 816 812 816 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Miyagi1">[46]</xref>
###xml 817 821 817 821 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Hakata1">[47]</xref>
###xml 1075 1079 1075 1079 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Turelli1">[12]</xref>
###xml 1080 1084 1080 1084 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Nguyen1">[48]</xref>
###xml 1085 1089 1085 1089 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Zhang3">[49]</xref>
###xml 223 228 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 838 841 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
###xml 1062 1065 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
Whether cytidine deamination is the principal mechanism for the antiviral activity of APOBEC3 proteins remains controversial [39]. APOBEC3 chimeric proteins and catalytically inactive mutants demonstrate that inhibition of HIV-1 can be achieved by A3G that lacks deaminase activity [40]-[42]. A3G can inhibit lentivirus reverse transcriptase (RT) and prevent accumulation of reverse transcripts and viral cDNA in target cells in a deamination-independent manner [35],[42]-[44]. Additionally, subsequent steps of viral integration have been shown to be affected by APOBEC3 proteins [37],[45]. The idea of deaminase-independent antiviral activity has been challenged by others who have argued that cytosine deamination is required for efficient inhibition of retroelements at low levels of APOBEC3 expression [38],[46],[47]. In the case of HBV, the mechanism for inhibition by APOBEC3 proteins is also controversial but has been suggested to be deaminase-independent due to infrequent editing, and may be caused by blocking reverse transcription and expression of HBV antigens [12],[48],[49].
###end p 10
###begin p 11
###xml 126 130 126 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Chen1">[14]</xref>
###xml 131 135 131 135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Bogerd1">[50]</xref>
###xml 136 140 136 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Bogerd2">[51]</xref>
###xml 241 245 241 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Muzyczka1">[52]</xref>
###xml 1071 1075 1071 1075 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Chen1">[14]</xref>
###xml 102 107 <span type="species:ncbi:9606">human</span>
###xml 196 202 <span type="species:ncbi:9606">humans</span>
###xml 742 762 <span type="species:ncbi:10794">minute virus of mice</span>
###xml 764 767 <span type="species:ncbi:10794">MVM</span>
###xml 803 825 <span type="species:ncbi:272636">adeno-associated virus</span>
###xml 827 830 <span type="species:ncbi:272636">AAV</span>
###xml 962 965 <span type="species:ncbi:272636">AAV</span>
###xml 1067 1070 <span type="species:ncbi:272636">AAV</span>
Although it lacks activity against retroviruses, A3A is a potent inhibitor of both parvovirus and the human transposon LINE-1 [14],[50],[51]. Parvoviruses are small eukaryotic viruses that infect humans and a variety of other animal species [52]. The parvovirus genome consists of a linear single-stranded DNA (ssDNA) molecule approximately 4.5 kb in length, with hairpin structures at both ends that function as origins for viral DNA replication. The genome contains two major ORFs that encode the nonstructural replication proteins (NS or Rep) and the structural capsid proteins (Cap). The family is divided into autonomous parvoviruses and dependoviruses, which require a helper virus for efficient replication and progeny production. The minute virus of mice (MVM) is an autonomous parvovirus while adeno-associated virus (AAV) is a dependovirus that uses adenovirus as a helper virus. In our previous studies we found that despite the absence of detectable AAV editing, mutations in conserved active site residues of A3A abrogated the antiviral activity against AAV [14].
###end p 11
###begin p 12
###xml 459 463 459 463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Muzyczka1">[52]</xref>
###xml 620 623 620 623 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Jarmuz1">[2]</xref>
###xml 624 628 624 628 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Chen1">[14]</xref>
A3A inhibition of parvovirus provides an attractive system in which to decipher the relative contribution of deamination and deaminase-independent mechanisms to antiviral activity. Unlike the other viruses known to be inhibited by APOBEC3 proteins, the parvoviruses replicate exclusively in the nucleus, do not pass through RNA intermediates, do not have a reverse transcription step in their replication schemes, and use DNA hairpins for priming replication [52]. Moreover, A3A is a simplified system for probing APOBEC3 functions because it has a single CDD and is not restricted to a specific subcellular compartment [2],[14].
###end p 12
###begin p 13
###xml 315 323 315 323 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 535 538 <span type="species:ncbi:272636">AAV</span>
###xml 611 614 <span type="species:ncbi:10794">MVM</span>
To ascertain whether deaminase activity is required for inhibition of parvovirus replication, and to understand the functional significance of amino acid divergence between A3A and A3G, we analyzed the properties of a panel of A3A point mutants and A3A/A3G chimeras. The proteins were tested for deaminase activity in vitro and for antiviral activity in rAAV production assays. We identify mutants that lack deaminase activity but retain the antiviral effect, supporting the idea of a deamination-independent mechanism. In addition to AAV, we show that A3A inhibits DNA replication of the autonomous parvovirus MVM. Chimeric A3A/A3G proteins generated by exchanging divergent sequences demonstrate loss-of-function for A3A and gain-of-function for A3G. Our mutants also reveal residues in the linker and pseudoactive site domains that are important for deamination, target specificity and antiviral activities of A3A. Together, these studies reveal domains of A3A that are responsible for its distinct antiviral activity and suggest that A3A can inhibit parvoviruses through a mechanism separate from its function as a cytidine deaminase.
###end p 13
###begin title 14
Results
###end title 14
###begin title 15
Inhibition of rAAV Production Is Not Dependent Upon the Deaminase Activity of A3A
###end title 15
###begin p 16
###xml 188 192 188 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Chen1">[14]</xref>
###xml 469 473 469 473 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Navaratnam1">[16]</xref>
###xml 474 478 474 478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-MacGinnitie1">[53]</xref>
###xml 564 568 564 568 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Bogerd1">[50]</xref>
###xml 616 625 616 625 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000439-g001">Figure 1A</xref>
###xml 297 300 <span type="species:ncbi:272636">AAV</span>
We previously showed that A3A antiviral activity was dependent on the integrity of conserved amino acids in the active site that are responsible for proton shuttling and zinc coordination [14]. These results suggested that the catalytic domain of A3A must be intact for antiviral activity against AAV. To extend these studies, we generated additional point mutations at conserved residues (F75 and F95) previously shown to be required for deaminase activity of APOBEC1 [16],[53]. We also mutated the 99SPC101 residues to AAA (SPC) in the active site domain of A3A [50]. The position of these mutants is indicated in Figure 1A.
###end p 16
###begin title 17
Deamination is not required for antiviral activity of A3A.
###end title 17
###begin p 18
###xml 250 252 250 252 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">28</sub>
###xml 257 258 257 258 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 498 506 498 506 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vitro</italic>
###xml 663 665 663 665 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">28</sub>
###xml 669 671 669 671 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">29</sub>
###xml 909 917 909 917 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 957 960 <span type="species:ncbi:272636">AAV</span>
###xml 1032 1035 <span type="species:ncbi:272636">AAV</span>
(A) Schematic of A3A and active site mutants. Domains marked are the cytidine deaminase domain (CDD), the linker (LINK), the pseudoactive site (PAS) and the hemagglutinin epitope tag (H). Active site residues conserved among APOBEC3 proteins (H-X-E-X28-PC-X4-C) are indicated in bold. Asterisks indicate specific mutations generated for this study; F75 is indicated with a red asterisk. (B) Immunofluorescence to detect HA-tagged APOBEC3 proteins (red) expressed by transfection in U2OS cells. (C) In vitro assay for cytidine deaminase activity. Proteins were generated by IVT, immuno-precipitated by the HA epitope, and incubated with a radiolabeled substrate (T28TCAT29). The deaminated molecules were cleaved by treatment with UDG followed by high pH, and the products were resolved by PAGE (upper panel). Arrows indicate the substrate and deaminated product. The panel below shows an immunoblot to detect in vitro translated proteins. (D) Inhibition of AAV. Production of rAAVLuc was assessed by transfection of 293T cells with AAV plasmids in the presence of APOBEC3 expression constructs (1 microg). Production of rAAV was assessed by transduction of target cells and quantitation of luciferase activity. Presented is the average of three independent experiments normalized to vector only control (mock). The panels below show immunoblots to detect HA-tagged wild type and mutant A3A proteins in transfected 293T cell lysates. Ku86 served as a loading control.
###end p 18
###begin p 19
###xml 106 115 106 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000439-g001">Figure 1B</xref>
###xml 225 234 225 234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000439-g001">Figure 1B</xref>
First, we determined the cellular localization of the mutant proteins in transfected U2OS and HeLa cells (Figure 1B and data not shown). Wild-type A3A was located throughout the cell, while A3G was predominantly cytoplasmic (Figure 1B). Most of the A3A mutants displayed cellular localization patterns similar to wild-type protein. The double mutant FF7595LL showed a nuclear punctate pattern (also observed in some cells transfected with E72Q and SPC), which might reflect misfolded protein.
###end p 19
###begin p 20
###xml 65 73 65 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 175 179 175 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Chen1">[14]</xref>
###xml 291 295 291 295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Hakata1">[47]</xref>
###xml 398 406 398 406 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 624 633 624 633 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat.1000439.s001">Figure S1</xref>
###xml 868 877 868 877 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000439-g001">Figure 1C</xref>
###xml 946 955 946 955 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat.1000439.s001">Figure S1</xref>
###xml 1342 1346 1342 1346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Chen1">[14]</xref>
###xml 1347 1351 1347 1351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Bogerd1">[50]</xref>
###xml 161 166 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 445 450 <span type="species:ncbi:4565">wheat</span>
We next measured the catalytic activity of the proteins using an in vitro deamination assay. We previously demonstrated deaminase activity for A3A packaged into HIV-1 virions [14]. To bypass the requirement for packaging, we directly immunoprecipitated A3A from lysates of transfected cells [47]. We further adapted the assay to control for different expression levels by generating A3A by coupled in vitro transcription/translation (IVT) using wheat germ extract. An advantage of this method is that it allows assessment of proteins that are unstable or difficult to express in cells, such as FF7595LL and A3A truncations (Figure S1). Cytidine deaminase activity of the immunoprecipitates was measured by incubation with a radiolabeled deoxyoligonucleotide containing a single deoxycytidine target site. Wild-type A3A protein generated by IVT had deaminase activity (Figure 1C) and demonstrated similar activity to A3A produced by transfection (Figure S1). These results showed that the IVT generated protein was catalytically active and also suggested that A3A does not require a mammalian cellular co-factor for its catalytic activity. Analysis of the active site mutants in the IVT system showed that, consistent with previous studies, mutants in conserved active site amino acids (H70R, E72Q, C106S, and SPC) had lost deaminase activity [14],[50]. Although the F75 and F95 residues have both been shown to be required for APOBEC1 deaminase activity, the F95L mutant of A3A retained deaminase activity in our analysis, while the F75L mutant was inactive.
###end p 20
###begin p 21
###xml 154 163 154 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000439-g001">Figure 1D</xref>
###xml 317 322 317 322 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 652 661 652 661 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000439-g001">Figure 1D</xref>
###xml 737 741 737 741 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Chen1">[14]</xref>
###xml 1011 1019 1011 1019 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 125 128 <span type="species:ncbi:272636">AAV</span>
###xml 350 353 <span type="species:ncbi:272636">AAV</span>
###xml 1209 1212 <span type="species:ncbi:272636">AAV</span>
###xml 1437 1440 <span type="species:ncbi:272636">AAV</span>
The antiviral activity of A3A mutants was compared to wild-type A3A and A3G by transfection of 293T cells in the recombinant AAV (rAAV) production assay (Figure 1D). The APOBEC3 expression vectors were cotransfected with plasmids required for rAAV replication and packaging. The Rep and Cap proteins were supplied in trans to allow replication of an AAV vector and packaging of the ssDNA genome into virus particles. In this study we employed rAAV expressing luciferase (rAAVLuc), which allowed for quantitative assessment of virus production by transduction of target cells. Immunoblotting confirmed that proteins of the expected size were expressed (Figure 1D). Wild-type A3A completely blocked rAAV production, as previously reported [14]. In contrast, neither A3G nor the active site A3A mutants H70R, E72Q, SPC and C106S inhibited rAAV production. The F95L mutant that retains deaminase activity was active against rAAV. Surprisingly, F75L also inhibited rAAV despite its lack of deaminase activity in the in vitro assay. The F75L protein is therefore a separation-of-function mutant of A3A that facilitates analysis of the relative contribution of the deaminase-dependent and -independent mechanisms to AAV inhibition. The double mutant FF7595LL did not inhibit rAAV production but was poorly expressed and showed altered cellular distribution. Together, these data demonstrate that deaminase activity is not required for the anti-AAV effect of A3A.
###end p 21
###begin title 22
A3A Inhibits Parvovirus Replication by a Deaminase-Independent Mechanism
###end title 22
###begin p 23
###xml 169 178 169 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000439-g002">Figure 2A</xref>
###xml 752 762 752 762 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat.1000439.s002">Figure S2A</xref>
###xml 767 775 767 775 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat.1000439.s008">Table S1</xref>
###xml 839 847 839 847 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1082 1086 1082 1086 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Thielen1">[54]</xref>
###xml 1182 1192 1182 1192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat.1000439.s002">Figure S2B</xref>
###xml 1503 1513 1503 1513 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat.1000439.s002">Figure S2B</xref>
###xml 1563 1571 1563 1571 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 26 29 <span type="species:ncbi:272636">AAV</span>
###xml 1612 1615 <span type="species:ncbi:272636">AAV</span>
To exclude differences in AAV inhibition due to disparities in protein expression levels, we compared the mutants F75L and F95L with wild-type A3A over a dose-response (Figure 2A). Immunoblotting revealed that expression levels of the mutants F75L and F95L were approximately ten-fold lower than wild-type A3A when equal amounts of DNA were transfected. However, despite differences in the deamination ability of the mutants, they displayed similar antiviral activity to wild-type A3A when equivalent protein levels were compared. We tested the F75L mutant against a panel of oligonucleotides that contained a cytosine in each of the possible tri-nucleotide configurations, but found no evidence of deamination above background levels on any sequence (Figure S2A and Table S1). Therefore the lack of detectable deaminase activity for F75L in vitro was not caused by an altered target sequence preference. We also tested the deaminase activity of A3A mutants in cell lysates by adapting the quantitative fluorescence resonance energy transfer (FRET) assay recently developed for A3G [54]. This FRET assay measures cleavage of a target oligonucleotide dual-labeled with fluorophores (Figure S2B). We observed dose-dependent deaminase activity with increasing amounts of cell lysates from 293T cells transfected with the A3A plasmid. Background levels of activity were obtained with the defective mutants E72Q and C106S. F95L showed deaminase activity in this assay, whereas F75L was not above background (Figure S2B). This result supports the observations from the in vitro deaminase assay and the conclusion that AAV is inhibited in the absence of deamination.
###end p 23
###begin title 24
###xml 20 23 <span type="species:ncbi:272636">AAV</span>
A3A mutants inhibit AAV DNA replication.
###end title 24
###begin p 25
###xml 697 700 681 684 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Dpn</italic>
(A) Titration of wild-type and mutant A3A expression vectors in rAAVLuc production assays. Production of rAAVLuc was assessed by transduction of target cells and quantitation of luciferase activity. Presented is the average of four independent experiments normalized to vector alone control (mock). The panels below show immunoblots to detect HA-tagged wild-type and mutant A3A proteins in transfected 293T cell lysates. (B) Southern blot detection of low molecular weight DNA extracted from 293T cells transfected for rAAVLuc production in the presence of mock (1 microg) A3G (1 microg), A3A (1, 0.1, 0.01 and 0.001 microg) and mutant A3A expression vectors (1 microg). The DNA was digested with Dpn-I, separated by gel electrophoresis, and hybridized with a radiolabeled luciferase probe.
###end p 25
###begin p 26
###xml 168 172 168 172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Chen1">[14]</xref>
###xml 347 356 347 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000439-g002">Figure 2B</xref>
###xml 607 616 607 616 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000439-g002">Figure 2B</xref>
###xml 27 30 <span type="species:ncbi:272636">AAV</span>
###xml 111 114 <span type="species:ncbi:272636">AAV</span>
###xml 649 652 <span type="species:ncbi:272636">AAV</span>
In our previous studies of AAV production in the presence of wild-type A3A, we found no detectable evidence of AAV sequence changes but viral replication was inhibited [14]. To detect effects of A3A on the accumulation of rAAV DNA, we used Southern blotting of low molecular weight DNA extracted from the transfected cells during rAAV production (Figure 2B). As controls, we compared the A3A mutants to wild-type A3A and A3G. Replicated rAAV DNA was detected by hybridization with a luciferase probe. Although F75L was slightly less effective than F95L, both mutants inhibited the accumulation of rAAV DNA (Figure 2B), suggesting that inhibition of AAV replication is not dependent on deamination.
###end p 26
###begin p 27
###xml 360 364 360 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Chen1">[14]</xref>
###xml 509 518 509 518 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000439-g003">Figure 3A</xref>
###xml 126 130 <span type="species:ncbi:10804?0.6129032258064516">AAV2</span>
###xml 180 183 <span type="species:ncbi:10794">MVM</span>
###xml 306 310 <span type="species:ncbi:10804?0.6129032258064516">AAV2</span>
###xml 844 847 <span type="species:ncbi:272636">AAV</span>
To examine the effect of A3A and mutants on replication of wild-type parvovirus genomes, we used two different viral systems. AAV2 depends upon helper virus for replication, while MVM replicates autonomously. First we used immunofluorescence to assess the effect of APOBEC3 proteins in cells infected with AAV2 and adenovirus helper virus. As previously shown [14], replication centers detected by staining for the viral Rep protein were present in cells that expressed A3G but were absent in those with A3A (Figure 3A). Advanced stage viral replication centers were detected in cells expressing inactive mutants. In contrast, A3A mutants that inhibited rAAV production (F75L and F95L) also blocked formation of viral replication centers. These data demonstrate that observations made with rAAV production also apply to inhibition of wild-type AAV replication.
###end p 27
###begin title 28
###xml 13 17 <span type="species:ncbi:10804?0.6129032258064516">AAV2</span>
###xml 22 25 <span type="species:ncbi:10794">MVM</span>
A3A inhibits AAV2 and MVM DNA replication.
###end title 28
###begin p 29
###xml 501 504 501 504 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Dpn</italic>
###xml 28 31 <span type="species:ncbi:272636">AAV</span>
###xml 131 134 <span type="species:ncbi:272636">AAV</span>
###xml 179 182 <span type="species:ncbi:272636">AAV</span>
###xml 295 298 <span type="species:ncbi:10794">MVM</span>
###xml 421 424 <span type="species:ncbi:10794">MVM</span>
###xml 576 579 <span type="species:ncbi:10794">MVM</span>
###xml 775 778 <span type="species:ncbi:10794">MVM</span>
(A) Inhibition of wild-type AAV replication. U2OS cells were transfected with plasmids for APOBEC3 proteins and then infected with AAV and adenovirus. HA-tagged APOBEC3 (red) and AAV Rep proteins (green) were detected by immunofluorescence using specific antibodies. (B) Inhibition of wild-type MVM replication. Southern blot detection of low molecular weight DNA extracted from A9 cells cotransfected with an infectious MVM clone together with APOBEC3A expression plasmids. The DNA was digested with Dpn-I, separated by gel electrophoresis and hybridized with a radiolabeled MVM probe. Left line is a marker (M). Replicative intermediates of ssDNA (SS), monomer (M), and dimer (D) are indicated to the right. Panel below shows immunoblots for APOBEC3 and the NS1 protein of MVM.
###end p 29
###begin p 30
###xml 145 154 145 154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000439-g003">Figure 3B</xref>
###xml 392 395 388 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bgl</italic>
###xml 427 436 423 432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000439-g003">Figure 3B</xref>
###xml 46 49 <span type="species:ncbi:10794">MVM</span>
###xml 201 204 <span type="species:ncbi:10794">MVM</span>
###xml 383 386 <span type="species:ncbi:10794">MVM</span>
###xml 514 517 <span type="species:ncbi:10794">MVM</span>
###xml 579 582 <span type="species:ncbi:10794">MVM</span>
Replication of an infectious plasmid clone of MVM was also dramatically inhibited by co-transfection of wild-type A3A, but not the C106S mutant (Figure 3B, lanes 1-3). Interestingly, replication of an MVM genome bearing a large in-frame deletion within the capsid gene, and therefore unable to generate the wild-type capsid proteins necessary to produce single-stranded progeny DNA (MVM-DeltaBglII), was also inhibited by A3A (Figure 3B, lanes 4-6). In separate experiments, the expression of the full spectrum of MVM RNA and protein generated from a non-replicating full-length MVM plasmid was not affected by expression of A3A (data not shown), suggesting that A3A directly affects parvovirus genome replication.
###end p 30
###begin title 31
The Linker and Pseudoactive Domains of A3A Are Required for Antiviral Activity
###end title 31
###begin p 32
###xml 290 298 290 298 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000439-g004">Figure 4</xref>
###xml 367 371 367 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Holden1">[55]</xref>
###xml 418 426 418 426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000439-g004">Figure 4</xref>
###xml 751 754 740 743 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Jarmuz1">[2]</xref>
###xml 814 823 803 812 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000439-g005">Figure 5A</xref>
###xml 846 849 835 838 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pml</italic>
###xml 924 927 913 916 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pml</italic>
###xml 1164 1167 1153 1156 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pml</italic>
###xml 1282 1292 1271 1281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat.1000439.s003">Figure S3A</xref>
###xml 1434 1438 1423 1427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Bogerd2">[51]</xref>
###xml 1550 1558 1539 1547 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1575 1577 1564 1566 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">28</sub>
###xml 1582 1584 1571 1573 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">28</sub>
###xml 1617 1626 1606 1615 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000439-g005">Figure 5B</xref>
###xml 1824 1833 1813 1822 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000439-g005">Figure 5C</xref>
###xml 2299 2308 2288 2297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000439-g005">Figure 5D</xref>
To identify further residues required for A3A antiviral activity, we compared the sequence of A3A to the C-terminus of A3B and A3G. Alignment of the amino acid sequences showed that A3A is most closely related to A3B. Two main regions with variable sequences (VS1 and VS2) differ from A3G (Figure 4). Using the structure of the C-terminal domain of A3G as a template [55], we predicted the secondary structure of A3A (Figure 4) and this suggested that the VS1 would be located in the loop between the beta2 strand and the alpha1 helix, and that VS2 partially overlaps with the alpha4 helix. To define regions of A3A responsible for the antiviral activity against parvoviruses, we tested the contribution of the linker and pseudoactive site subdomains [2]. We first generated chimeric proteins between A3A and A3G (Figure 5A) joined at the shared PmlI site. The N-terminus of A3A (residues 1-119) was fused to the C-terminal PmlI fragment of A3G (residues 306-384) to form the chimera A3ApmlA3G. The reciprocal chimera A3GpmlA3A was also generated. We also assessed the activity of the C-terminus of A3G (A3G-CT, residues M197 to N384) and a fusion with A3A at the PmlI site (A3G-CTpmlA3A). Cellular localization of the mutants was tested by immunofluorescence in transfected cells (Figure S3A). We found that localization of the chimeric proteins to the cytoplasm was determined by the N-terminal domain of A3G as previously reported [51]. We also measured the deaminase activity of chimeric proteins immunoprecipitated from transfected cells in the in vitro assay with the T28CCCGT28 deoxyoligonucleotide substrate (Figure 5B, upper panel). Full-length A3A and A3G both produced robust deamination, but all of the chimeras were less active. The mutants were also tested for activity against rAAV in the transfection assay (Figure 5C). Neither A3G nor A3G-CT had any inhibitory effect against rAAV despite being expressed well in transfected cells. Fusion of the linker and pseudoactive site subdomains of A3A onto A3G or A3G-CT was not sufficient to confer antiviral activity (A3GpmlA3A and A3G-CTpmlA3A). The A3ApmlA3G chimera, which possesses the linker and pseudoactive site of A3G fused onto A3A, showed diminished antiviral activity. This reduction was confirmed in a dose-response titration (Figure 5D). Together these data suggest that the linker and pseudoactive site regions of A3A are important for deamination and antiviral activity, but that these domains are not sufficient to confer activity to A3G.
###end p 32
###begin title 33
Alignment of APOBEC3 amino acid sequences for A3A with the C-terminus of A3B and A3G.
###end title 33
###begin p 34
###xml 87 90 87 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pml</italic>
###xml 664 668 657 661 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Bordoli1">[77]</xref>
Residues exchanged in A3A are boxed and the mutant designation is indicated above. The PmlI site and stretches of variable sequence VS1 and VS2 switched in the chimeras are also indicated. The asterisks mark individual amino acid mutants, and the diamond indicates the start of A3G-CT (residues 197-384). Residue numbers are indicated on the right side. Predicted secondary structure of A3A is indicated below the alignment with alpha-helices in black and stranded beta-sheets in grey. A3A secondary structure modeling was generated by Swiss-Model using the crystal structure of the C-terminal fragment of A3G (Protein Data Bank accession number 3E1A) as template [77].
###end p 34
###begin title 35
###xml 21 23 21 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ml</italic>
Activity of A3A/A3G PmlI based chimeras.
###end title 35
###begin p 36
###xml 239 242 239 242 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Pml</italic>
###xml 254 262 254 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vitro</italic>
(A) Schematic of A3A (dark grey) and A3G (light grey). Domains marked are the cytidine deaminase domains (CDD), the linker (LINK), the pseudoactive site (PAS), and the hemagglutinin epitope tag (H). Below are the chimeras generated at the PmlI site. (B) In vitro assays for cytidine deaminase activity. Proteins were immunoprecipitated from transfected cells by the HA epitope and incubated with the indicated radiolabeled substrate in UDG-dependent assays. The upper panel uses a substrate oligonucleotide with target sequence CCCG, and the middle panel uses an oligonucleotide with the specific A3A target sequence TCA. The substrate and deaminated products are indicated. The bottom panel shows an immunoblot to detect proteins in immunoprecipitates. A band corresponding to the light-chain IgG used for immunoprecipitation is indicated (*). (C) Production of rAAV in the presence of APOBEC3 proteins. 293T cells were transfected with APOBEC3 constructs (1 microg, except for A3A 0.1 microg), together with plasmids required for rAAVLuc production. Virus production was assessed by transduction of target cells and quantitation by luciferase assay. Panels below show immunoblots for APOBEC3 proteins (HA) in transfected cells and Ku86 as a loading control. (D) Dose-response for A3A and the A3ApmlA3G chimera in the rAAV production assay. Panels below show immunoblots for APOBEC3 (HA) and Ku86 proteins in transfected cells.
###end p 36
###begin p 37
###xml 58 67 58 67 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000439-g005">Figure 5B</xref>
###xml 240 244 240 244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Chen1">[14]</xref>
###xml 245 249 245 249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Yu1">[33]</xref>
###xml 250 254 250 254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Langlois1">[56]</xref>
###xml 255 259 255 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Beale1">[59]</xref>
###xml 531 539 531 539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat.1000439.s008">Table S1</xref>
###xml 610 619 610 619 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000439-g005">Figure 5B</xref>
###xml 775 784 775 784 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000439-g005">Figure 5B</xref>
###xml 946 950 946 950 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Langlois1">[56]</xref>
###xml 1129 1133 1129 1133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Chen2">[17]</xref>
###xml 1134 1138 1134 1138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Chen3">[60]</xref>
###xml 1162 1170 1162 1170 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1170 1174 1170 1174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Holden1">[55]</xref>
###xml 1287 1295 1287 1295 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1445 1449 1445 1449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Holden1">[55]</xref>
Careful inspection of the deaminase assay autoradiograms (Figure 5B, upper panel) revealed that the deaminated products for A3A and A3G have slightly different mobilities, which likely reflects differences in deamination target specificity [14],[33],[56]-[59]. The deamination product for A3GpmlA3A migrated similarly to that of A3A, suggesting it had gained the target site specificity of A3A. To test this possibility, we analyzed the deaminase activity on a deoxyoligonucleotide containing the specific A3A target sequence TCA (Table S1). While A3A was highly active on the TCA substrate, A3G was inactive (Figure 5B, middle panel). Although the level of deamination by the A3GpmlA3A chimera was less than that of A3A, this mutant was similarly active on both substrates (Figure 5B, compare upper and middle panels). These observations suggest that the region encompassing the linker and pseudoactive site is involved in target site selection [56]. In our assay the C-terminal fragment of A3G was inactive, although recent studies reported that a similar fragment of A3G (residues 198-384) showed mutator activity in bacteria [17],[60] and deaminase activity in vitro[55]. However, these studies used GST-tagged A3G-CT in the bacterial assays or purified recombinant protein in their in vitro assays, while we have analyzed protein from cell lysates. Furthermore, A3G-CT was shown to be significantly less active than the full-length protein [55]. Our results may also reflect differences in experimental conditions or that protein produced by transfection may be less active due to RNA inhibition or lack of dimerization.
###end p 37
###begin title 38
Deaminase Activity Is Dispensable for Activity against rAAV
###end title 38
###begin p 39
###xml 154 162 154 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000439-g004">Figure 4</xref>
###xml 245 254 245 254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000439-g006">Figure 6A</xref>
###xml 568 576 564 572 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000439-g004">Figure 4</xref>
###xml 646 655 642 651 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000439-g006">Figure 6A</xref>
###xml 740 750 736 746 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat.1000439.s003">Figure S3B</xref>
###xml 837 845 833 841 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 853 862 849 858 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000439-g006">Figure 6B</xref>
###xml 1206 1215 1198 1207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000439-g006">Figure 6C</xref>
###xml 1347 1356 1339 1348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat.1000439.s004">Figure S4</xref>
###xml 1575 1584 1543 1552 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat.1000439.s004">Figure S4</xref>
###xml 1201 1204 <span type="species:ncbi:272636">AAV</span>
Based on the analysis of chimeric proteins, we generated further mutants in which non-conserved residues of A3A were substituted with those from A3G (see Figure 4). Amino acids that differed between the two proteins were changed throughout A3A (Figure 6A). Most of the mutants consisted of A3A residues replaced with the analogous A3G sequence. Two residues lacking in A3G were deleted from A3A (DeltaWG), and in another mutant unique residues from A3G were inserted into A3A (EPWVR). The two main variable regions that contain stretches of divergence (VS1 and VS2 in Figure 4) were switched in two stages that changed 3 or 4 residues at a time (Figure 6A). All mutants displayed the same pattern of cellular localization as wild-type A3A (Figure S3B). Mutant proteins were synthesized by IVT and evaluated for deaminase activity in the in vitro assay (Figure 6B). Mutants PT, MAK, and SK retained wild-type levels of activity. The EPWVR and DeltaWG mutants had diminished activity compared to wild-type A3A. The chimeras in variable stretches VS1 and VS2 lacked detectable deaminase activity. When these mutants were included in the rAAV production assay, all of them retained the ability to inhibit AAV (Figure 6C). The VS1 mutants with diminished antiviral activity (GFLE and PHKHGFLE) were also compared to wild-type A3A over a dose response (Figure S4). When similar levels of protein were compared for their effect on rAAV production, the VS1 mutants GFLE and PHKHGFLE showed less activity than wild-type A3A (approximately75% inhibition compared to approximately95%) (Figure S4). This observation suggests that the VS1 region in A3A contributes to the antiviral activity. Together these data demonstrate that residues outside of the putative enzymatic active site of A3A, in both the N-terminus and C-terminus, are required for efficient deamination but that this does not correlate with antiviral activity against parvovirus replication.
###end p 39
###begin title 40
Mutants of A3A with residues replaced with the corresponding sequences of A3G.
###end title 40
###begin p 41
###xml 215 223 215 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vitro</italic>
###xml 349 351 349 351 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">28</sub>
###xml 356 358 356 358 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">28</sub>
(A) Schematic of variable segments VS1 and VS2, and the chimeric mutants generated for A3A in these regions. The VS1 segment corresponds to A3A residues 60 to 67, and VS2 corresponds to A3A residues 132 to 137. (B) In vitro deamination assay. Proteins were immunoprecipitated from transfected cells and incubated with radiolabeled oligonucleotide (T28CCCGT28) for 16 h in UDG-dependent assays. Arrows indicate the substrate and deaminated product. The panel below shows an immunoblot to detect proteins in immunoprecipitates. (C) Production of rAAV in the presence of wild-type (0.1 microg) and mutant A3A proteins (1 microg). Panels below show immunoblots for APOBEC3 proteins (HA) in transfected cells and Ku86 as a loading control.
###end p 41
###begin title 42
###xml 17 20 <span type="species:ncbi:272636">AAV</span>
Activity against AAV Can Be Conferred to A3G
###end title 42
###begin p 43
###xml 350 359 350 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000439-g007">Figure 7A</xref>
###xml 494 503 494 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000439-g007">Figure 7B</xref>
###xml 593 602 593 602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000439-g007">Figure 7C</xref>
###xml 950 959 950 959 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat.1000439.s005">Figure S5</xref>
###xml 1046 1054 1046 1054 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1102 1111 1102 1111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat.1000439.s006">Figure S6</xref>
###xml 1279 1288 1279 1288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat.1000439.s006">Figure S6</xref>
###xml 558 561 <span type="species:ncbi:272636">AAV</span>
###xml 813 816 <span type="species:ncbi:272636">AAV</span>
###xml 1185 1188 <span type="species:ncbi:272636">AAV</span>
Analysis of the A3A mutants suggested that the two stretches of residues divergent between A3A and A3G (VS1 and VS2) are important for deamination, and may play a role in antiviral function. Therefore, we determined whether the reciprocal switch (where residues in A3G were substituted with the sequences from A3A) would generate a gain-of-function (Figure 7A). Sequences from A3A were incorporated into constructs that express the C-terminal fragment of A3G which can localize in the nucleus (Figure 7B). The mutant proteins were tested for their effect on AAV in the virus production assay (Figure 7C). Proteins of the expected size were expressed at similar levels. The C-terminal fragment that contained the complete sequence from VS1 of A3A (A3G-CT/KNLLCGFY) acquired significant inhibitory activity against AAV. It was less active than wild-type A3A and reduced rAAV production by approximately 50% when equal levels of protein where compared (Figure S5). When incorporated into full-length A3G, the VS1 region of A3A increased deamination in vitro, whereas the VS2 sequences decreased activity (Figure S6). Incorporation of the A3A sequences into full-length A3G did not confer AAV inhibition, presumably due to cytoplasmic localization or interference by the N-terminus (Figure S6). Thus A3G-CT/KNLLCGFY provides the first gain-of-function mutant for A3G and demonstrates that the VS1 region of A3A (residues 60 to 67) contributes to the antiviral activity against parvovirus.
###end p 43
###begin title 44
Identification of a gain-of-function mutant for A3G.
###end title 44
###begin p 45
###xml 848 849 848 849 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 698 701 <span type="species:ncbi:272636">AAV</span>
(A) Schematic of full-length A3G and the C-terminal fragment A3G-CT. Chimeras of A3G-CT were generated with variable segments VS1 and VS2 replaced with sequences of A3A. (B) Immunofluorescence to detect localization of HA-tagged APOBEC3 and chimeric proteins (red) expressed by transfection in U2OS cells. Cell nuclei were detected by staining with DAPI (blue). (C) Production of rAAV in the presence of APOBEC3 proteins. Virus production was assessed by transduction of target cells and quantitation by luciferase assay. Immunoblots show similar expression levels for APOBEC proteins in transfected cells. Ku86 served as a loading control. The A3G-CT/KNLLCGFY mutant demonstrated activity against AAV. The asterisks indicate that the inhibition with A3A and A3G-CT/KNLLCGFY was statistically significant (p<0.001) when compared to mock by Student t test.
###end p 45
###begin title 46
Discussion
###end title 46
###begin p 47
###xml 700 704 700 704 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Navaratnam1">[16]</xref>
###xml 705 709 705 709 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-MacGinnitie1">[53]</xref>
###xml 956 960 956 960 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Chen2">[17]</xref>
###xml 961 965 961 965 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Holden1">[55]</xref>
###xml 1028 1036 1028 1036 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1303 1311 1303 1311 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1439 1443 1439 1443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Thielen1">[54]</xref>
###xml 1614 1618 1614 1618 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Chen1">[14]</xref>
###xml 85 88 <span type="species:ncbi:272636">AAV</span>
###xml 294 297 <span type="species:ncbi:272636">AAV</span>
###xml 417 420 <span type="species:ncbi:272636">AAV</span>
###xml 550 553 <span type="species:ncbi:272636">AAV</span>
###xml 1513 1516 <span type="species:ncbi:272636">AAV</span>
###xml 1582 1585 <span type="species:ncbi:272636">AAV</span>
In this report we provide multiple pieces of evidence to show that A3A inhibition of AAV can occur through a deaminase-independent mechanism. Mutation of A3A active site residues that are essential for catalytic activity (H70R, E72Q, SPC99-101AAA and C106S) led to the loss of activity against AAV. However, other mutants (F75L and mutants in VS1 and VS2) separated the deaminase activity from the ability to inhibit AAV. Together these data indicate that the integrity of the active site is important but that deaminase activity is not required for AAV inhibition. In APOBEC1, aromatic residues analogous to F75L and F95L of A3A are required for both deaminase activity and binding to nucleic acids [16],[53]. In the case of A3A, we found that F95 is not required for deaminase activity. This result probably reflects the differences in structure and nucleic acid specificity between APOBEC3 proteins and APOBEC1, as revealed by recent structural studies [17],[55]. We found that the F75L mutant was deaminase-defective in our in vitro deaminase assay. The lack of deaminase activity on a panel of target oligonucleotides demonstrated that the F75L A3A mutant is truly deaminase-deficient, and has not simply changed its target site preference and eluded detection in the deaminase assay. Although the in vitro deaminase assay has limitations, we demonstrated that lysates containing F75L also lacked deaminase activity in the FRET assay [54]. Evidence that deaminase activity is not essential for inhibition of AAV by A3A is consistent with the absence of signs of deamination in AAV DNA in cells expressing A3A [14].
###end p 47
###begin p 48
###xml 97 101 93 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Aguiar1">[35]</xref>
###xml 102 106 98 102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Holmes1">[39]</xref>
###xml 200 204 196 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Newman1">[41]</xref>
###xml 205 209 201 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Bishop1">[42]</xref>
###xml 416 420 412 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Schumacher1">[38]</xref>
###xml 421 425 417 421 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Miyagi1">[46]</xref>
###xml 426 430 422 426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Browne1">[61]</xref>
###xml 45 48 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 538 541 <span type="species:ncbi:272636">AAV</span>
###xml 676 679 <span type="species:ncbi:272636">AAV</span>
Deaminase-independent inhibition of DeltaVif-HIV and retroelements by A3G has been controversial [35],[39]. The deaminase-defective A3G mutants in E259 retains anti-viral activity when over-expressed [41],[42]. However, when equivalent proteins levels are compared in transient transfections or in stable cell lines, the deaminase deficient mutant has significantly less potent antiviral activity than wild-type A3G [38],[46],[61]. In our studies we assessed the dose response of A3A mutants by comparing their antiviral activity against AAV in titration experiments. We identified deaminase-defective mutants (F75L and mutants in VS2) that displayed similar activity against AAV as wild-type A3A when analyzed at comparable protein levels. In addition, the F75L and VS2 mutants displayed the same subcellular localization as the wild-type protein and thus their phenotype cannot be ascribed to protein mislocalization.
###end p 48
###begin p 49
###xml 276 280 276 280 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Cen1">[19]</xref>
###xml 281 285 281 285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Huthoff1">[62]</xref>
###xml 410 411 410 411 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</underline>
###xml 411 414 411 414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Harris2">[9]</xref>
###xml 415 419 415 419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Iwatani1">[21]</xref>
###xml 420 424 420 424 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Yu1">[33]</xref>
###xml 425 429 425 429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Suspene1">[57]</xref>
###xml 430 434 430 434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Beale1">[59]</xref>
###xml 492 493 492 493 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</underline>
###xml 495 499 495 499 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Chen1">[14]</xref>
###xml 673 674 673 674 <underline xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</underline>
###xml 841 845 841 845 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Langlois1">[56]</xref>
###xml 922 925 922 925 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Conticello1">[1]</xref>
###xml 249 254 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
In addition to providing evidence for deaminase-independent antiviral activity, our study also offers insights into the structural basis of APOBEC3 protein function. The linker and pseudoactive site domains in the N-terminus of A3G are required for HIV-1 virion incorporation [19],[62]. We demonstrate that these domains also influence the target site specificity of APOBEC3. A3G prefers the target site (T/C)CC[9],[21],[33],[57],[59], while A3A is more flexible, showing preference for (T/C)CA [14]. Replacement of the linker and pseudoactive sub-domains at the end of A3G with those from A3A modified the target site preference towards the A3A-specific consensus target TCA. Thus, A3A residues in the C-terminus contribute to its target specificity, in agreement with data from chimeric and mutant proteins of other APOBEC3 family members [56]. Residues in the VS2 region have been implicated in target site specificity [1], but in our hands the exchange of VS2 residues between A3A and A3G did not affect target specificity.
###end p 49
###begin p 50
###xml 38 46 38 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 151 155 151 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Hache1">[20]</xref>
###xml 156 160 156 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Iwatani1">[21]</xref>
###xml 161 165 161 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Navarro1">[28]</xref>
###xml 166 170 166 170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Newman1">[41]</xref>
###xml 171 175 171 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Chen3">[60]</xref>
###xml 320 323 320 323 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#8211;4</sub>
###xml 412 420 408 416 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 441 449 437 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000439-g006">Figure 6</xref>
###xml 523 528 519 524 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">23&#8211;28</sub>
###xml 534 535 530 531 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 767 776 763 772 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat.1000439.s006">Figure S6</xref>
###xml 888 892 884 888 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Chen1">[14]</xref>
###xml 893 897 889 893 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Bogerd1">[50]</xref>
###xml 1079 1083 1075 1079 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Holden1">[55]</xref>
###xml 1392 1401 1388 1397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat.1000439.s006">Figure S6</xref>
###xml 1679 1683 1675 1679 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Chen3">[60]</xref>
It is unclear why A3A has more potent in vitro deaminase activity than other APOBEC3 proteins. Deaminase activity of A3G resides in the C-terminal CDD [20],[21],[28],[41],[60], which shares 68% identity with A3A. An intriguing difference between A3A and A3G is the presence of two additional residues (WG) within the PCX2-4C motif of A3A. Deletion of these amino acids in the A3A/DeltaWG mutant slightly reduced in vitro deaminase activity (Figure 6). The variable region VS1 is situated immediately upstream of the H-X-E-X23-28-P-C-X4-C conserved motif, and replacement of A3A sequences with those from A3G caused a decrease in deaminase activity. Substitution of the VS1 region in A3G with sequences from A3A increased deaminase activity compared to wild-type A3G (Figure S6). This suggests that the VS1 region (residues 60-67) may contribute to the increased enzymatic activity of A3A [14],[50]. Interestingly, the VS1 region in located in the active center loop 3 of the C-terminal domain of A3G and disruption of this loop results in greatly impaired A3G deaminase activity [55]. In the variable region VS2, substitution of A3A amino acids with those from A3G also decreased deamination, suggesting that this region is important for catalytic activity. This observation is supported by the decrease in deaminase activity observed for the reciprocal A3G mutants (A3G/YDP and A3G/YDPLYK) (Figure S6). Together these results indicate that regions outside of the active site contribute to catalytic activity of A3A. In support of our observations, a recent mutagenesis study of A3G also suggested that C-terminal residues (residues 276-384) are important for deaminase activity [60].
###end p 50
###begin p 51
###xml 124 128 124 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Aguiar1">[35]</xref>
###xml 129 133 129 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Holmes1">[39]</xref>
###xml 318 322 318 322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Mbisa1">[37]</xref>
###xml 323 327 323 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Bishop1">[42]</xref>
###xml 328 332 328 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Holmes2">[44]</xref>
###xml 333 337 333 337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Luo2">[45]</xref>
###xml 438 446 438 446 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 498 502 498 502 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Iwatani2">[63]</xref>
###xml 560 564 560 564 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Turelli1">[12]</xref>
###xml 681 685 681 685 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Nguyen1">[48]</xref>
###xml 895 899 895 899 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Chen1">[14]</xref>
###xml 1101 1105 1101 1105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Iwatani1">[21]</xref>
###xml 1106 1110 1106 1110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Iwatani2">[63]</xref>
###xml 1815 1819 1815 1819 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Niewiadomska1">[64]</xref>
###xml 1820 1824 1820 1824 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Chiu2">[65]</xref>
###xml 2003 2007 2003 2007 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Nash1">[66]</xref>
###xml 2109 2117 2109 2117 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 2202 2206 2202 2206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Nash2">[67]</xref>
###xml 108 111 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
###xml 520 523 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
###xml 687 690 <span type="species:ncbi:272636">AAV</span>
###xml 830 833 <span type="species:ncbi:10794">MVM</span>
###xml 1873 1876 <span type="species:ncbi:272636">AAV</span>
###xml 1936 1939 <span type="species:ncbi:272636">AAV</span>
###xml 1987 1990 <span type="species:ncbi:272636">AAV</span>
###xml 2186 2189 <span type="species:ncbi:272636">AAV</span>
Multiple mechanisms have been proposed to explain the deaminase-independent inhibition of retroelements and HBV by APOBEC3G [35],[39]. In the case of retroviruses, the APOBEC3 proteins have been suggested to inhibit RT, prevent accumulation of reverse transcripts and viral cDNA in target cells, and block integration [37],[42],[44],[45]. Biochemical studies have shown that purified recombinant A3G inhibited RT-catalyzed DNA elongation in vitro and this was independent of its deaminase activity [63]. A3G can inhibit HBV in the absence of extensive editing [12], and has been suggested to be due to inhibition of early steps in viral reverse transcription and strand elongation [48]. AAV inhibition differs from these other systems because it does not involve an RT-mediated step or any RNA substrates. Since A3A also inhibits MVM replication and does not affect production of viral proteins [14], we favor the idea that A3A inhibits parvovirus replication through a direct interaction with the viral DNA or the replication machinery. Binding to ssDNA by A3G is proposed to inhibit RT processivity [21],[63], and binding of A3A to ssDNA in the parvovirus genome could physically block movement of the DNA polymerase along the viral template. Although this inhibition would be independent of catalytic activity, amino acids in the active site may be required for efficient nucleic acid binding, explaining the loss of antiviral activity for mutants such as E72Q or C106S. Preliminary results suggest that the F75L mutant retains its ability to bind nucleic acid (data not shown). Potential binding sites could be the viral ITR or the ssDNA/dsDNA junction, which may reduce Rep binding and inhibit DNA synthesis. A3A is not found in high molecular weight complexes that have been reported to modulate A3G activity [64],[65], however we cannot exclude the possibility that AAV inhibition might be mediated through A3A interactions with AAV Rep or cellular proteins that are required for AAV replication [66]. It will be interesting to investigate whether recombinant A3A can block viral DNA replication in an in vitro replication assay where we could test the direct activity of A3A on AAV replication [67]. This approach, however, is currently limited by the requirement for purified recombinant A3A and its mutants.
###end p 51
###begin p 52
###xml 152 159 152 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 247 254 247 254 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 364 368 356 360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Peng1">[68]</xref>
###xml 582 591 570 579 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat.1000439.s007">Figure S7</xref>
###xml 839 843 827 831 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Chen1">[14]</xref>
###xml 844 848 832 836 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Bogerd1">[50]</xref>
###xml 849 853 837 841 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Bogerd2">[51]</xref>
###xml 854 858 842 846 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Niewiadomska1">[64]</xref>
###xml 859 863 847 851 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Muckenfuss1">[69]</xref>
###xml 864 868 852 856 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Hulme1">[71]</xref>
###xml 217 220 <span type="species:ncbi:272636">AAV</span>
###xml 415 418 <span type="species:ncbi:272636">AAV</span>
###xml 699 702 <span type="species:ncbi:272636">AAV</span>
Although 293 cells are a standard system used to study parvovirus replication, it remains unclear whether endogenous A3A restricts parvovirus infection in vivo. It is unknown which cells represent the primary site of AAV infection and replication in vivo. It has been shown that expression of APOBEC3 proteins is induced in response to interferon-alpha (IFNalpha) [68]. The levels of A3A that achieve inhibition of AAV in transfected cells are within the range of endogenous A3A levels detected in peripheral blood mononuclear cells (PBMCs) and macrophages activated with IFNalpha (Figure S7). Therefore, it would be interesting to test whether cells refractory to parvovirus replication will allow AAV replication when endogenous A3A levels are reduced. In addition to parvoviruses, A3A is active against LINE1 and other retrotransposons [14],[50],[51],[64],[69]-[71] where hypermutation is not detected. It will be informative to determine whether this occurs by a mechanism similar to parvovirus inhibition. In summary, our study demonstrates that the DNA cytidine deaminase activity of A3A is not required for inhibition of parvovirus replication. The combination of the single-domain cytidine deaminase A3A with the simple model system of parvovirus replication provides a valuable tool to uncover new mechanisms for the antiviral activity of the APOBEC3 proteins.
###end p 52
###begin title 53
Materials and Methods
###end title 53
###begin title 54
Cell Lines
###end title 54
###begin p 55
###xml 299 300 293 294 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 19 24 <span type="species:ncbi:9606">human</span>
###xml 218 224 <span type="species:ncbi:9913">bovine</span>
293T, HeLa, A9 and human osteosarcoma U2OS cell lines were purchased from the American Tissue Culture Collection. Cells were grown as monolayers in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum and antibiotics at 37degreesC in a humid atmosphere containing 5% CO2.
###end p 55
###begin title 56
Expression Plasmids
###end title 56
###begin p 57
###xml 223 227 223 227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Chen1">[14]</xref>
###xml 336 344 336 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat.1000439.s008">Table S1</xref>
###xml 564 568 564 568 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Xiao1">[72]</xref>
###xml 474 477 <span type="species:ncbi:272636">AAV</span>
###xml 744 747 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
Expression plasmids encoding cDNAs for A3A (NM_145699) and A3G (NM_021822) and the A3A mutants H70R, E72Q, and C106S in the pcDNA3.1 (+) vector with a hemagglutinin (HA) tag at the C-terminus have been previously described [14]. New A3A and A3G mutants were generated by site-directed mutagenesis using the QuikChange kit (Stratagene) (Table S1). The truncated form of A3G (A3G-CT, residues 197-384) was generated by PCR amplification of its C-terminus. Plasmids expressing AAV Rep/Cap proteins (pXX2) and the adenovirus helper proteins (pXX6) have been described [72]. The rAAV vector plasmid (pACLALuc) consists of the luciferase gene amplified from pGL3basic (Promega) cloned into an ITR-flanked expression cassette under the control of the CMV promoter and the BGH polyadenylation signal (pACLA). The complete ITR-flanked expression cassette in pACLALuc is 4.3 Kb.
###end p 57
###begin title 58
###xml 26 29 <span type="species:ncbi:272636">AAV</span>
Production of Recombinant AAV
###end title 58
###begin p 59
###xml 73 77 73 77 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Chen1">[14]</xref>
###xml 78 82 78 82 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Xiao1">[72]</xref>
###xml 125 126 125 126 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 550 554 530 534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Narvaiza1">[73]</xref>
###xml 12 15 <span type="species:ncbi:272636">AAV</span>
Recombinant AAV production assays were performed as previously described [14],[72]. Briefly, 293T cells were seeded at 0.5x106 cells/well in 6-well plates and the next day were co-transfected with pXX6 (2.25 microg), pXX2 (0.75 microg), pACLALuc (0.75 microg) and APOBEC3 expression vector (1 microg unless otherwise stated) or pcDNA3.1(+) control vector (1 microg). Dose-response titrations maintained the total amount of effector DNA by addition of pcDNA3.1(+). Transfections were performed in duplicate or triplicate using polyethyleneimine (PEI) [73]. Cells were harvested 72 h post-transfection after two washes in ice-cold PBS, and one third of each sample was removed for immuno-blotting. The other two thirds of the cells were used to generate rAAVLuc virus lysates by freeze/thaw cycles followed by centrifugation. Virus lysates were used to transduce 293T cells in 48 wells in triplicate. Transduced cells were incubated with Steady-Glo luciferase substrate reagent (Promega) 48 h post-transduction and lucifierase activity was quantified in triplicate in 96 well Lumiplates (Greiner Bio-One) in a TopCount NXT scintillation and luminescence counter (PerkinElmer). rAAV production experiments are presented as mean+SEM of the relative value (%) of at least three independent experiments, and compared to mock transfections with pcDNA3.1(+).
###end p 59
###begin title 60
Immunoblotting
###end title 60
###begin p 61
###xml 54 58 54 58 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Chen1">[14]</xref>
###xml 168 169 168 169 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 172 173 172 173 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 185 186 185 186 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 188 189 188 189 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 199 200 199 200 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 923 927 <span type="species:ncbi:9925">goat</span>
###xml 933 938 <span type="species:ncbi:10090">mouse</span>
###xml 962 973 <span type="species:ncbi:3704">horseradish</span>
Immunoblotting was performed essentially as described [14]. Cell pellets from rAAVLuc production assays were lysed in lysis buffer (137 mM NaCl, 2.68 mM KCl, 10.1 mM Na2HPO4, 1.76 mM KH2PO4, 1 mM NaO3V, 20 mM beta-glycerol phosphate, 20 mM NaF, 0.1% NP40, and 0.025% Triton-X 100) supplemented with Complete protease inhibitor cocktail (Roche) for 30 min on ice. The lysates were clarified by centrifugation at 10,000xg for 20 min. Protein concentrations from whole cell lysates were quantified by BCA assay (Bio-Rad), and 20 microg of protein was loaded per well onto polyacrylamide gels. Proteins were separated in 4-12% or 12% Acrylamide Bis-Tris NuPage gels in MOPS buffer (Invitrogen) and transferred onto Hybond nitrocellulose membranes (Amersham Biosciences). Membranes were probed with anti-HA 16b12 monoclonal antibody (mAb) (Covance) and anti-Ku86 mAb (Santa Cruz). Bound antibody was detected by incubation with goat anti-mouse antibody conjugated to horseradish peroxidase (Jackson ImmunoResearch), and the bands were visualized with enhanced chemiluminiscence reagent (ECL Western Lightning Kit, PerkinElmer) followed by autoradiography.
###end p 61
###begin title 62
Immunofluorescence
###end title 62
###begin p 63
###xml 74 78 74 78 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Chen1">[14]</xref>
###xml 508 512 <span type="species:ncbi:9925">goat</span>
###xml 518 523 <span type="species:ncbi:10090">mouse</span>
###xml 844 847 <span type="species:ncbi:272636">AAV</span>
###xml 1002 1005 <span type="species:ncbi:272636">AAV</span>
###xml 1235 1238 <span type="species:ncbi:272636">AAV</span>
APOBEC3 protein localization was determined by indirect immunoflorescence [14]. U2OS or HeLa cells were grown on glass coverslips in 24 well plates and transfected with 0.8 microg APOBEC3 expression vector using Lipofectamine 2000 (Invitrogen). After 36-48 h, cells were washed with PBS, fixed with 3% paraformaldehyde for 20 min and extracted with 0.5% Triton X-100 in PBS for 10 min. Cells were incubated with 3% BSA for 30 min, followed by incubation with anti-HA mAb 16b12 (1:2000). A 1:2000 dilution of goat anti-mouse conjugated Alexa Fluor 568 (Invitrogen) and DAPI (Sigma Aldrich) in 3% BSA in PBS was added to cells and samples were incubated for 1 h at room temperature. The coverslips were mounted in Fluoromount-G (Southern Biotech) and cells were visualized by fluorescence microscopy (Diaphot 300 inverted microscope, Nikon). For AAV replication U2OS cells were seeded on glass coverslips and transfected with APOBEC3 expression vector, and infected 16 h post-transfection with wild-type AAV and/or adenovirus. After 24 hr, the cells were fixed and stained with anti-HA and anti-Rep antibodies and DAPI as described above. Rep from the input virus is undetectable in this assay, so positive Rep staining is indicative of AAV replication.
###end p 63
###begin title 64
Southern Blot Hybridization
###end title 64
###begin p 65
###xml 84 86 84 86 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
###xml 137 141 137 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Stracker1">[74]</xref>
###xml 685 689 657 661 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Stracker1">[74]</xref>
###xml 708 711 680 683 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Dpn</italic>
###xml 875 878 847 850 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sma</italic>
###xml 1143 1145 1115 1117 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
###xml 1220 1228 1192 1200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat.1000439.s008">Table S1</xref>
###xml 1246 1248 1218 1220 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
###xml 21 24 <span type="species:ncbi:272636">AAV</span>
Low molecular weight AAV episomal DNA was analyzed by Southern hybridization with a 32P-labeled luciferase probe as previously described [74]. Briefly, 293T cells grown in 6 well tissue culture plates to 95% confluency were co-transfected with plasmids for rAAV production using Lipofectamine 2000 following the manufacturer's protocol. The following effector plasmids were included: pcDNA3.1(+) (1 microg), A3G (1ug), A3A (1 microg, 0.1 microg, 0.01 microg and 0.001 microg), F75L (1 microg) and F95L (1 microg). After 48 h, the cells were collected and washed in PBS. One third of each sample was removed for immunoblotting. DNA was isolated from pellets by a modified HIRT protocol [74] and digested with DpnI (New England Biolabs) to remove input plasmid. DNA was processed by gel electrophoresis on a 1% agarose gel in TAE buffer. The pACLALuc plasmid was digested with SmaI as control. The gel was depurinated in 0.2 M HCl, denatured in 1 M NaCl, 0.5 M NaOH, and neutralized in 0.5 M Tris pH 7.5, 1.5 M NaCl. DNA was then transferred to a Hybond XL membrane (Amersham Biosciences) and UV-cross linked. The membrane was hybridized with a 32P labeled luciferase probe generated by PCR using the primers described in Table S1 and labeled with 32P dCTP using Radivue II labeling kit (Amersham), and visualized in a FLA-5100 phosphorimager (Fuji).
###end p 65
###begin p 66
###xml 63 66 59 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bgl</italic>
###xml 108 112 104 108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Tullis1">[75]</xref>
###xml 46 49 <span type="species:ncbi:10794">MVM</span>
###xml 54 57 <span type="species:ncbi:10794">MVM</span>
Southern blot replication assays of wild-type MVM and MVM-DeltaBglII were performed as previously described [75].
###end p 66
###begin title 67
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vitro</italic>
In vitro Deaminase Assays
###end title 67
###begin p 68
###xml 30 31 30 31 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 945 953 925 933 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat.1000439.s008">Table S1</xref>
###xml 966 968 946 948 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
293T cells were seeded at 5x105 cells/well in 6-well plates and transfected after one day with 3 microg of APOBEC3 expression vector. Two days post-transfection, the cells were rinsed twice with cold PBS and lysed for 30 min on ice in lysis buffer (50 mM Tris, pH 8.0, 40 mM KCl, 50 mM NaCl, 5 mM EDTA, 0.1% Triton X-100, 10 mM DTT). Lysates were clarified by centrifugation at 13,000xg for 10 min and pre-cleared with 50 microl of High flow protein-G-Sepharose (Amersham). The lysate was incubated with anti-HA mAb 3F10 (Roche) for 2 h at 4degreesC. The lysate-antibody was then incubated with High flow protein-G-Sepharose for 1-2 h at 4degreesC. The resin was washed three times with lysis buffer. One-fifth of the resin was removed for immunoblot analysis and the remainder was washed once with deaminase reaction buffer (40 mM Tris, pH 8.0, 10% glycerol, 40 mM KCl, 50 mM NaCl, 5 mM EDTA, and 1 mM DTT). PAGE purified deoxyoligonucleotide (Table S1) was 5'-end 32P labeled and added into 20 microl of deaminase reaction buffer. The reaction was incubated at 37degreesC for 20 h, stopped by heating to 90degreesC for 5 min, cooled on ice, and then centrifuged to collect the resin at the bottom of tube. The supernatant was incubated with uracil DNA glycosylase (New England Biolabs) in buffer containing 20 mM Tris, pH 8.0, 1 mM DTT for 1 h at 37degreesC and treated with 150 mM NaOH for 1 h at 37degreesC. The samples were incubated at 95degreesC for 5 min, 4degreesC for 2 min and separated by 15% TBE/urea-PAGE. The gel was dried, exposed to a phosphorimager screen and analyzed using a FLA-5100 scanner (Fuji).
###end p 68
###begin p 69
###xml 4 12 4 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 70 75 <span type="species:ncbi:4565">Wheat</span>
For in vitro synthesis of A3A and mutants we employed the TNT Coupled Wheat Germ Extract System (Promega) using T7 polymerase. Translation reactions were performed with non-labeled amino acids following the manufacturer's protocol in 50 microl final volume that included 1 microg of pcDNA3.1(+) plasmid encoding APOBEC3. Reactions were incubated for 90 min at 30degreesC. After incubation, 450 microl of TritonX-100 buffer (50 mM Tris, pH 8.0, 40 mM KCl, 50 mM NaCl, 5 mM EDTA, 0.1% Triton X-100, 10 mM DTT) were added to the reactions and used to analyze deaminase activity after immunoprecipitation as described above.
###end p 69
###begin p 70
###xml 316 318 302 304 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
In order to measure deaminase activity directly from IVT reactions, after 90 min incubation at 30degreesC translation reactions were centrifuged at 10,000xg for 1 min. An aliquot of supernatant (5 microl) was removed for immunoblot analysis. The reaction mixture (15 microl of supernatant) was incubated with 5'-end 32P labeled deoxyoligonucleotide in 30 microl of deaminase reaction buffer and assayed for deaminase activity following the same procedure described above.
###end p 70
###begin title 71
FRET-Based Deaminase Activity Assay from Cell Lysates
###end title 71
###begin p 72
###xml 121 127 121 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 127 131 127 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Thielen1">[54]</xref>
###xml 163 164 163 164 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 550 558 534 542 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat.1000439.s008">Table S1</xref>
To quantify deaminase activity from cell lysates, we used a modification of the FRET-based protocol described by Thielen et al.[54]. 293T cells were seeded at 1x106 cells/well in 6 cm plates and a day later transfected with 8 microg of APOBEC3 expression vector. After 36 to 48 h, cells were resuspended in lysis buffer (200 microl) and lysates were obtained as described above. Cell lysate (10 microl) was mixed with 70 microl of FRET deaminase buffer (40 mM Tris, pH 8.0, 40 mM KCl, 50 mM NaCl, 5 mM EDTA) containing 10 pmol of dual-labeled probe (Table S1) and 0.4 units of UDG (New England Biolabs). Reactions were incubated at 37degreesC for 90 min followed by addition of 4 microl of 4N NaOH and incubation at 37degreesC for 30 min. Reactions were neutralized with 4 microl of 4N HCl and 36 microl of 1 M Tris-HCl (pH 8). 6FAM fluorescence was measured at 25degreesC in an Mx30005P (Stratagene). Two-fold serial dilutions of each lysate were analyzed in duplicate. Fluorescence detected in 293T cells transfected with pcDNA3.1 (mock) was substracted from all samples and deaminase activity is shown as relative fluorescence units (RFU).
###end p 72
###begin title 73
Detection of Endogenous A3A
###end title 73
###begin p 74
###xml 185 186 185 186 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 373 374 373 374 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 677 681 677 681 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000439-Alexander1">[76]</xref>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 565 570 <span type="species:ncbi:9606">human</span>
###xml 1071 1077 <span type="species:ncbi:9986">rabbit</span>
Human monocytes were purified from leukocyte enriched blood samples (New York Blood Center) using CD14+ magnetic beads (Miltenyi Biotec) according to manufacturer instructions. The CD14+ monocytes were cultured with 50 ng/ml GM-CSF (Invitrogen) for 7 days in order to differentiate them into macrophages. The monocyte-derived macrophages were plated in 12 well plates at 106 cells per well and cultured with or without 2000U of Universal Type I Interferon (PBL Biomedical Laboratories) for 20 hours. The cells were then collected in lysis buffer. Cell lysates from human peripheral blood mononuclear cells (PBMCs) were obtained from F. Chisari (The Scripps Research Institute) [76]. PBMCs were treated with 1000U of IFN-alpha or kept untreated for 24 hrs before cell lysates were generated. Lysates of PBMCs (60 microg) and macrophages (30 microg) of each sample were run on 4-12% or 12% Bis-Tris gels and analyzed by immunoblotting as described above. Anti-A3A (raised against an N-terminal peptide) (1:250 dilution) or anti-recombinant A3A (1:1000 dilution) polyclonal rabbit sera were used for A3A detection as described.
###end p 74
###begin title 75
Supporting Information
###end title 75
###begin p 76
###xml 43 51 43 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in-vitro</italic>
###xml 205 213 205 213 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in-vitro</italic>
###xml 544 546 544 546 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
###xml 557 559 557 559 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">28</sub>
###xml 563 565 563 565 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">28</sub>
###xml 1039 1046 1039 1046 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="sec" rid="s4">Methods</xref>
APOBEC3A proteins synthesized from coupled in-vitro transcription-translation are active in UDG-dependent deaminase assays. Deaminase activity of A3A and mutant proteins generated by cell transfection and in-vitro coupled transcription-translation (IVT) was analyzed in UDG-dependent deaminase assays. (A) 293T cells were transfected with plasmids for A3A and mutants. Cells were harvested at 48 hrs post-transfection, and lysates were subject to immunoprecipitation (IP) with anti-HA antibody (3F10). 4/5 of the IP was incubated with a 5'-end 32P labeled T28TCAT28 deoxyoligonucleotide and tested in UDG-dependent deaminase assays. Arrows indicate substrate deoxyoligonucleotide and cleaved deaminated product. Bottom panel shows an immunoblot corresponding to 1/5 of the IP analyzed with an anti-HA antibody (16B12). Asterisks indicate bands corresponding to IgG light chain. A3A truncations are: TruncA (aa 1-145), TruncB (aa 1-165), and TruncC (aa 53-199). (B) Wild-type and mutant A3A proteins were synthesized by IVT as described in Methods. pcDNA3.1(+) was included in IVTs as mock. A3A proteins were immunoprecipitated with 3F10 antibody and tested in the UDG-dependent deaminase assay. Immunoprecipitated A3A from transfected cells was included as a control. Middle panel shows 1/5 of the IP protein analyzed by immunoblotting with 16B12 antibody. Bottom panel shows immunoblotting of lysates to demonstrate that equal amounts of protein were generated by IVT. (C) Wild-type and mutant A3A proteins were tested directly from IVT reactions for deaminase activity. Bottom panel shows an immunoblot of 1/5 of the IVT-synthesized proteins loaded into the deaminase reactions.
###end p 76
###begin p 77
(1.92 MB PDF)
###end p 77
###begin p 78
Click here for additional data file.
###end p 78
###begin p 79
###xml 301 309 301 309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat.1000439.s008">Table S1</xref>
###xml 389 391 389 391 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
###xml 845 853 845 853 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat.1000439.s008">Table S1</xref>
Lack of deaminase activity for F75L is not due to modified target sequence preference and is supported by the lack of deamination measured by FRET. (A) To rule out differences in target sequence preference, A3A and F75L were tested in UDG-dependent deaminase assays against 16 different target sites (Table S1). Target sequence preference of A3A and F75L was determined on a panel of four 32P-labeled deoxyoligonucleotide substrates, each containing four target sites. The -1 base is shown at the top of each lane and the +1 base is shown on the left. The structure of the cleaved products is shown on the right. (B) Quantification of deaminase acitivity by FRET in cell lysates obtained from 293T cells transfected with A3A, E72Q, F75L, F95L and C106S. Cell lysates were incubated with a dual-labeled probe containing the CCCG target sequence (Table S1). The TAMRA fluorophore quenches emission by the 6FAM fluorophore. After deamination and treatment with UDG and high pH, 6FAM fluorescence emission can be detected from the cleaved probe. Two-fold serial dilutions of each lysate were analyzed by duplicate and represented as mean+/-SEM. Results show that deaminase activity is detected in cell lysates obtained from cells transfected with A3A and F95L, while deaminase activity of E72Q, F75L and C106S is not distinguishable from the background level. Bottom panel shows an immunoblot of cell lysates.
###end p 79
###begin p 80
(2.23 MB PDF)
###end p 80
###begin p 81
Click here for additional data file.
###end p 81
###begin p 82
Localization of A3A/A3G chimeras. Immunofluorescence to detect localization of HA-tagged APOBEC3 and chimeric proteins (red) expressed by transfection in U2OS cells. Cell nuclei were detected by staining with DAPI (blue). (A) Localization of wild-type APOBEC3 proteins and A3A/A3G chimeras. (B) Localization of A3A mutants with sequences incorporated from A3G.
###end p 82
###begin p 83
(9.29 MB PDF)
###end p 83
###begin p 84
Click here for additional data file.
###end p 84
###begin p 85
Inhibition of rAAV production by A3A/A3G chimeras in the VS1 region. Dose-response for A3A and mutant proteins in the rAAV production assay. Virus production was assessed by transduction of target cells and quantitation by luciferase assay. Panels below show immunoblots for APOBEC3 (HA) and Ku86 proteins in transfected cells.
###end p 85
###begin p 86
(0.39 MB PDF)
###end p 86
###begin p 87
Click here for additional data file.
###end p 87
###begin p 88
###xml 519 520 495 496 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
Dose-response antiviral activity of A3G-CT/KNLLCGFY. Comparison of A3A and A3G-CT/KNLLCGFY antiviral activity over a dose-response in rAAV production assays. Comparable levels of A3A and A3G-CT/KNLLCGFY resulted in approximately95% and approximately50% inhibition respectively. Bottom panels show immunoblots for A3A and A3G-CT/KNLLCGFY (HA), and Ku86 protein as a loading control. The asterisks indicate that the inhibition with A3G-CT/KNLLCGFY was statistically significant (p<0.001) when compared to mock by Student t test.
###end p 88
###begin p 89
(0.53 MB PDF)
###end p 89
###begin p 90
Click here for additional data file.
###end p 90
###begin p 91
###xml 269 277 269 277 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vitro</italic>
Chimeric A3G proteins with sequences replaced with VS1 and VS2 from A3A. (A) Immunofluorescence to detect localization of HA-tagged APOBEC3 and chimeric proteins (red) expressed by transfection in U2OS cells. Cell nuclei were detected by staining with DAPI (blue). (B) In vitro deamination assay. Proteins were immunoprecipitated from transfected cells and incubated with the radiolabeled substrate in the standard assay. Arrows indicate the substrate and deaminated product. The panel below shows an immunoblot to detect proteins in immunoprecipitates. Arrows indicate bands corresponding to APOBEC3 proteins. Asterisk indicates bands corresponding to IgG light chain. (C) Production of rAAV in the presence of APOBEC3 proteins. Virus production was assessed by transduction of target cells and quantitation by luciferase assay. Immunoblots show similar expression levels for APOBEC3 proteins (HA) in transfected cells. Ku86 served as a loading control.
###end p 91
###begin p 92
(3.93 MB PDF)
###end p 92
###begin p 93
Click here for additional data file.
###end p 93
###begin p 94
###xml 333 338 <span type="species:ncbi:9606">human</span>
###xml 395 401 <span type="species:ncbi:9986">rabbit</span>
###xml 684 689 <span type="species:ncbi:9606">human</span>
###xml 760 766 <span type="species:ncbi:9986">rabbit</span>
Antiviral activity of A3A is achieved with physiological levels of transfected A3A. (A) Antiviral activity of A3A was analyzed in a rAAVLuc production experiment over a dose response. Expression levels of A3A were analyzed by immunoblotting using an anti-HA antibody (top blot), and compared to endogenous levels of A3A expressed in human PBMCs incubated with IFNalpha. A3A was detected using a rabbit polyclonal antisera raised against an N-terminal A3A specific peptide (bottom blot). Arrow indicates bands corresponding to A3A. Background band below A3A is indicated with an asterisk. (B) In panel B the expression levels of A3A are compared to endogenous levels of A3A induced in human macrophages in response to IFNalpha. A3A was detected with polyclonal rabbit serum generated to recombinant A3A protein.
###end p 94
###begin p 95
(1.09 MB PDF)
###end p 95
###begin p 96
Click here for additional data file.
###end p 96
###begin p 97
Oligonucleotides used in this study. Sequences corresponding to the oligonucleotides used in this study. Name, template and type of experiments are indicated for each oligonucleotide. D.A. (deaminase assays). N/A (not applicable).
###end p 97
###begin p 98
(0.08 MB DOC)
###end p 98
###begin p 99
Click here for additional data file.
###end p 99
###begin p 100
###xml 307 310 <span type="species:ncbi:10794">MVM</span>
We thank F. Gage and R.J. Samulski for reagents. We thank F. Chisari for PBMCs lysates. We thank A. Denli, C. Lilley, and members of the Weitzman lab for helpful discussions. We thank L. Fourgeaud for technical assistance with immunofluorescence microscopy and Lisa Burger and Chaoyang Ye for help with the MVM experiments.
###end p 100
###begin title 101
References
###end title 101
###begin article-title 102
The AID/APOBEC family of nucleic acid mutators.
###end article-title 102
###begin article-title 103
An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22.
###end article-title 103
###begin article-title 104
Rapid evolution of primate antiviral enzyme APOBEC3G.
###end article-title 104
###begin article-title 105
Messenger RNA editing in mammals: new members of the APOBEC family seeking roles in the family business.
###end article-title 105
###begin article-title 106
Retroviral restriction by APOBEC proteins.
###end article-title 106
###begin article-title 107
The APOBEC3 cytidine deaminases: an innate defensive network opposing exogenous retroviruses and endogenous retroelements.
###end article-title 107
###begin article-title 108
Role and mechanism of action of the APOBEC3 family of antiretroviral resistance factors.
###end article-title 108
###begin article-title 109
###xml 15 20 <span type="species:ncbi:9606">human</span>
###xml 40 45 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein.
###end article-title 109
###begin article-title 110
DNA deamination mediates innate immunity to retroviral infection.
###end article-title 110
###begin article-title 111
###xml 32 37 <span type="species:ncbi:9606">human</span>
Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts.
###end article-title 111
###begin article-title 112
###xml 72 77 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA.
###end article-title 112
###begin article-title 113
###xml 14 31 <span type="species:ncbi:10407">hepatitis B virus</span>
Inhibition of hepatitis B virus replication by APOBEC3G.
###end article-title 113
###begin article-title 114
###xml 17 22 <span type="species:ncbi:10090">mouse</span>
APOBEC3 inhibits mouse mammary tumour virus replication in vivo.
###end article-title 114
###begin article-title 115
###xml 34 56 <span type="species:ncbi:272636">adeno-associated virus</span>
APOBEC3A is a potent inhibitor of adeno-associated virus and retrotransposons.
###end article-title 115
###begin article-title 116
Cytidine deaminase. The 2.3 A crystal structure of an enzyme: transition-state analog complex.
###end article-title 116
###begin article-title 117
Evolutionary origins of apoB mRNA editing: catalysis by a cytidine deaminase that has acquired a novel RNA-binding motif at its active site.
###end article-title 117
###begin article-title 118
###xml 45 50 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Structure of the DNA deaminase domain of the HIV-1 restriction factor APOBEC3G.
###end article-title 118
###begin article-title 119
The APOBEC-2 crystal structure and functional implications for the deaminase AID.
###end article-title 119
###begin article-title 120
###xml 24 29 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The interaction between HIV-1 Gag and APOBEC3G.
###end article-title 120
###begin article-title 121
The retroviral hypermutation specificity of APOBEC3F and APOBEC3G is governed by the C-terminal DNA cytosine deaminase domain.
###end article-title 121
###begin article-title 122
###xml 64 69 <span type="species:ncbi:9606">human</span>
Biochemical activities of highly purified, catalytically active human APOBEC3G: correlation with antiviral effect.
###end article-title 122
###begin article-title 123
###xml 29 64 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
###xml 94 99 <span type="species:ncbi:9606">human</span>
Amino-terminal region of the human immunodeficiency virus type 1 nucleocapsid is required for human APOBEC3G packaging.
###end article-title 123
###begin article-title 124
###xml 49 54 <span type="species:ncbi:9606">human</span>
Distinct viral determinants for the packaging of human cytidine deaminases APOBEC3G and APOBEC3C.
###end article-title 124
###begin article-title 125
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 Vif, APOBEC, and intrinsic immunity.
###end article-title 125
###begin article-title 126
###xml 80 85 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
APOBEC3G is incorporated into virus-like particles by a direct interaction with HIV-1 Gag nucleocapsid protein.
###end article-title 126
###begin article-title 127
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 10 13 <span type="species:ncbi:11786">MLV</span>
HIV-1 and MLV Gag proteins are sufficient to recruit APOBEC3G into virus-like particles.
###end article-title 127
###begin article-title 128
###xml 59 94 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Viral RNA is required for the association of APOBEC3G with human immunodeficiency virus type 1 nucleoprotein complexes.
###end article-title 128
###begin article-title 129
Complementary function of the two catalytic domains of APOBEC3G.
###end article-title 129
###begin article-title 130
###xml 36 41 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Specific packaging of APOBEC3G into HIV-1 virions is mediated by the nucleocapsid domain of the gag polyprotein precursor.
###end article-title 130
###begin article-title 131
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 36 41 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Human APOBEC3G is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs.
###end article-title 131
###begin article-title 132
7SL RNA mediates virion packaging of the antiviral cytidine deaminase APOBEC3G.
###end article-title 132
###begin article-title 133
###xml 28 63 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
APOBEC3G incorporation into human immunodeficiency virus type 1 particles.
###end article-title 133
###begin article-title 134
###xml 83 86 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome.
###end article-title 134
###begin article-title 135
###xml 17 22 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Hypermutation of HIV-1 DNA in the absence of the Vif protein.
###end article-title 135
###begin article-title 136
APOBEC3 proteins and reverse transcription.
###end article-title 136
###begin article-title 137
###xml 141 146 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Virion-associated uracil DNA glycosylase-2 and apurinic/apyrimidinic endonuclease are involved in the degradation of APOBEC3G-edited nascent HIV-1 DNA.
###end article-title 137
###begin article-title 138
###xml 0 35 <span type="species:ncbi:11676">Human immunodeficiency virus type 1</span>
Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration.
###end article-title 138
###begin article-title 139
###xml 30 35 <span type="species:ncbi:9606">human</span>
###xml 76 111 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
The DNA deaminase activity of human APOBEC3G is required for Ty1, MusD, and human immunodeficiency virus type 1 restriction.
###end article-title 139
###begin article-title 140
APOBEC-mediated viral restriction: not simply editing?
###end article-title 140
###begin article-title 141
###xml 96 101 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The enzymatic activity of CEM15/Apobec-3G is essential for the regulation of the infectivity of HIV-1 virion but not a sole determinant of its antiviral activity.
###end article-title 141
###begin article-title 142
Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity.
###end article-title 142
###begin article-title 143
Antiviral potency of APOBEC proteins does not correlate with cytidine deamination.
###end article-title 143
###begin article-title 144
###xml 54 59 <span type="species:ncbi:9606">human</span>
###xml 76 111 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Inhibition of formula-primed reverse transcription by human APOBEC3G during human immunodeficiency virus type 1 replication.
###end article-title 144
###begin article-title 145
###xml 41 46 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G.
###end article-title 145
###begin article-title 146
###xml 56 91 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation.
###end article-title 146
###begin article-title 147
###xml 70 105 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Enzymatically active APOBEC3G is required for efficient inhibition of human immunodeficiency virus type 1.
###end article-title 147
###begin article-title 148
###xml 36 41 <span type="species:ncbi:10090">mouse</span>
###xml 46 51 <span type="species:ncbi:9606">human</span>
Reversed functional organization of mouse and human APOBEC3 cytidine deaminase domains.
###end article-title 148
###begin article-title 149
###xml 38 55 <span type="species:ncbi:10407">hepatitis B virus</span>
Deamination-independent inhibition of hepatitis B virus reverse transcription by APOBEC3G.
###end article-title 149
###begin article-title 150
###xml 100 117 <span type="species:ncbi:10407">hepatitis B virus</span>
Cytidine deaminase APOBEC3B interacts with heterogeneous nuclear ribonucleoprotein K and suppresses hepatitis B virus expression.
###end article-title 150
###begin article-title 151
###xml 79 84 <span type="species:ncbi:9606">human</span>
APOBEC3A and APOBEC3B are potent inhibitors of LTR-retrotransposon function in human cells.
###end article-title 151
###begin article-title 152
Cellular inhibitors of long interspersed element 1 and Alu retrotransposition.
###end article-title 152
###begin article-title 153
###xml 0 12 0 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Parvoviridae</italic>
Parvoviridae: The viruses and their replication.
###end article-title 153
###begin article-title 154
Mutagenesis of apobec-1, the catalytic subunit of the mammalian apolipoprotein B mRNA editing enzyme, reveals distinct domains that mediate cytosine nucleoside deaminase, RNA binding, and RNA editing activity.
###end article-title 154
###begin article-title 155
T cells contain an RNase-insensitive inhibitor of APOBEC3G deaminase activity.
###end article-title 155
###begin article-title 156
Crystal structure of the anti-viral APOBEC3G catalytic domain and functional implications.
###end article-title 156
###begin article-title 157
Mutational comparison of the single-domained APOBEC3C and double-domained APOBEC3F/G anti-retroviral cytidine deaminases provides insight into their DNA target site specificities.
###end article-title 157
###begin article-title 158
###xml 84 87 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
APOBEC3G is a single-stranded DNA cytidine deaminase and functions independently of HIV reverse transcriptase.
###end article-title 158
###begin article-title 159
RNA editing enzyme APOBEC1 and some of its homologs can act as DNA mutators.
###end article-title 159
###begin article-title 160
Comparison of the differential context-dependence of DNA deamination by APOBEC enzymes: correlation with mutation spectra in vivo.
###end article-title 160
###begin article-title 161
Extensive mutagenesis experiments corroborate a structural model for the DNA deaminase domain of APOBEC3G.
###end article-title 161
###begin article-title 162
###xml 15 20 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Restriction of HIV-1 by APOBEC3G is cytidine deaminase-dependent. Virology: Epub ahead of print.
###end article-title 162
###begin article-title 163
###xml 77 112 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Identification of amino acid residues in APOBEC3G required for regulation by human immunodeficiency virus type 1 Vif and Virion encapsidation.
###end article-title 163
###begin article-title 164
###xml 36 41 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Deaminase-independent inhibition of HIV-1 reverse transcription by APOBEC3G.
###end article-title 164
###begin article-title 165
Differential inhibition of long interspersed element 1 by APOBEC3 does not correlate with high-molecular-mass-complex formation or P-body association.
###end article-title 165
###begin article-title 166
High-molecular-mass APOBEC3G complexes restrict Alu retrotransposition.
###end article-title 166
###begin article-title 167
###xml 36 58 <span type="species:ncbi:272636">adeno-associated virus</span>
Complete in vitro reconstitution of adeno-associated virus DNA replication requires the minichromosome maintenance complex proteins.
###end article-title 167
###begin article-title 168
###xml 46 68 <span type="species:ncbi:272636">adeno-associated virus</span>
Purification of host cell enzymes involved in adeno-associated virus DNA replication.
###end article-title 168
###begin article-title 169
###xml 46 51 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Myeloid differentiation and susceptibility to HIV-1 are linked to APOBEC3 expression.
###end article-title 169
###begin article-title 170
###xml 25 30 <span type="species:ncbi:9606">human</span>
APOBEC3 proteins inhibit human LINE-1 retrotransposition.
###end article-title 170
###begin article-title 171
APOBEC3B and APOBEC3F inhibit L1 retrotransposition by a DNA deamination-independent mechanism.
###end article-title 171
###begin article-title 172
Selective inhibition of Alu retrotransposition by APOBEC3G.
###end article-title 172
###begin article-title 173
###xml 37 59 <span type="species:ncbi:272636">adeno-associated virus</span>
Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus.
###end article-title 173
###begin article-title 174
###xml 76 81 <span type="species:ncbi:10090">mouse</span>
Effect of adenovirus-mediated RNA interference on endogenous microRNAs in a mouse model of multidrug resistance protein 2 gene silencing.
###end article-title 174
###begin article-title 175
###xml 19 48 <span type="species:ncbi:10804">adeno-associated virus type 2</span>
The Rep protein of adeno-associated virus type 2 interacts with single-stranded DNA-binding proteins that enhance viral replication.
###end article-title 175
###begin article-title 176
###xml 58 78 <span type="species:ncbi:10794">minute virus of mice</span>
The minor capsid protein VP1 of the autonomous parvovirus minute virus of mice is dispensable for encapsidation of progeny single-stranded DNA but is required for infectivity.
###end article-title 176
###begin article-title 177
###xml 25 40 <span type="species:ncbi:10090">transgenic mice</span>
###xml 87 92 <span type="species:ncbi:9606">human</span>
Derivation of HLA-A11/Kb transgenic mice: functional CTL repertoire and recognition of human A11-restricted CTL epitopes.
###end article-title 177
###begin article-title 178
Protein structure homology modeling using SWISS-MODEL workspace.
###end article-title 178
###begin p 179
The authors have declared that no competing interests exist.
###end p 179
###begin p 180
###xml 541 544 <span type="species:ncbi:10794">MVM</span>
This work was funded by fellowships from the Instituto de Salud Carlos III/Consejo Superior de Investigaciones Cientificas/Salk Institute and the Lynn Streim Postdoctoral Endowment Fellowship (IN). EL is a potdoctoral fellow of The Irvington Institute Fellowship Program of the Cancer Research Institute. Work in the Weitzman lab was partially supported by a Pioneer Developmental Chair and by a grant from NIH (AI74967). NRL is a fellow of the Elizabeth Glaser Pediatric AIDS Foundation and is supported by a grant from NIH (AI058864). The MVM experiments in the Pintel lab were supported by grants from NIH (AI21302 and AI46458). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 180

